Update shared on 03 Dec 2025
Analysts have maintained their price target on Concord Biotech at ₹1,736.67, reflecting unchanged assumptions on discount rate, revenue growth, profit margin, and future valuation multiples while reiterating confidence in the existing outlook.
What's in the News
- The board has approved an investment of up to INR 100 million in a captive hybrid solar power project for the Limbasi plant, supporting long term energy cost management and sustainability goals (company filing).
- The company plans to enter into an agreement with a relevant party to execute the captive hybrid solar power project, indicating progress on planned capacity and infrastructure enhancements (company filing).
- A board meeting is scheduled on November 13, 2025 to consider and approve standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2025 (exchange notice).
- The November 13, 2025 board meeting will also address other business matters, which may include additional strategic or operational decisions to be disclosed (exchange notice).
Valuation Changes
- Fair Value Estimate remains unchanged at approximately ₹1,736.67, indicating no revision to the intrinsic value outlook.
- The Discount Rate is stable at about 12.76 percent, suggesting no change in the perceived risk profile or cost of capital.
- Revenue Growth is effectively unchanged at around 25.55 percent, reflecting consistent assumptions on medium term expansion.
- The Net Profit Margin is broadly steady at roughly 32.26 percent, indicating no material shift in expected profitability levels.
- The Future P/E Multiple is stable at about 37.43 times, implying no adjustment to long term valuation multiples applied to earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.